Novel computational biology modeling system can accurately forecast response to neoadjuvant therapy in early breast cancer.

ABSTRACT:

Background

Generalizable population-based studies are unable to account for individual tumor heterogeneity that contributes to variability in a patient's response to physician-chosen therapy. Although molecular characterization of tumors has advanced precision medicine, in early-stage and locally advanced breast cancer patients, predicting a patient's response to neoadjuvant therapy (NAT) remains a gap in current clinical practice. Here, we perform a study in an independent cohort of early-stage and locally advanced breast cancer patients to forecast tumor response to NAT and assess the stability of a previously validated biophysical simulation platform.

Methods

A single-blinded study was performed using a retrospective database from a single institution (9/2014-12/2020). Pa

SUBMITTER: Peterson JR 

PROVIDER: S-EPMC10170712 | biostudies-literature | 2023 May

REPOSITORIES: biostudies-literature